JPH0320206A - Skin cosmetic - Google Patents
Skin cosmeticInfo
- Publication number
- JPH0320206A JPH0320206A JP15638589A JP15638589A JPH0320206A JP H0320206 A JPH0320206 A JP H0320206A JP 15638589 A JP15638589 A JP 15638589A JP 15638589 A JP15638589 A JP 15638589A JP H0320206 A JPH0320206 A JP H0320206A
- Authority
- JP
- Japan
- Prior art keywords
- whey
- skin
- collagen synthesis
- acid
- skin cosmetic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002537 cosmetic Substances 0.000 title claims abstract description 27
- 102000008186 Collagen Human genes 0.000 claims abstract description 46
- 108010035532 Collagen Proteins 0.000 claims abstract description 46
- 229920001436 collagen Polymers 0.000 claims abstract description 45
- 108010046377 Whey Proteins Proteins 0.000 claims abstract description 39
- 102000007544 Whey Proteins Human genes 0.000 claims abstract description 39
- 239000005862 Whey Substances 0.000 claims abstract description 38
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 34
- 230000015572 biosynthetic process Effects 0.000 claims abstract description 32
- 238000003786 synthesis reaction Methods 0.000 claims abstract description 31
- 241000283690 Bos taurus Species 0.000 claims abstract description 12
- 241000124008 Mammalia Species 0.000 claims abstract description 7
- 241000283707 Capra Species 0.000 claims abstract description 5
- 241000282414 Homo sapiens Species 0.000 claims abstract description 5
- 241001494479 Pecora Species 0.000 claims abstract description 4
- 241000282898 Sus scrofa Species 0.000 claims abstract 2
- 239000002253 acid Substances 0.000 claims description 13
- 210000003022 colostrum Anatomy 0.000 claims description 11
- 235000021277 colostrum Nutrition 0.000 claims description 11
- 230000002708 enhancing effect Effects 0.000 claims description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 11
- 210000002950 fibroblast Anatomy 0.000 abstract description 7
- 230000037303 wrinkles Effects 0.000 abstract description 6
- 239000006210 lotion Substances 0.000 abstract description 5
- 239000000126 substance Substances 0.000 abstract description 5
- 230000006870 function Effects 0.000 abstract description 4
- 230000004215 skin function Effects 0.000 abstract description 4
- 230000009471 action Effects 0.000 abstract description 3
- 239000006071 cream Substances 0.000 abstract description 3
- 230000002500 effect on skin Effects 0.000 abstract description 3
- 238000002156 mixing Methods 0.000 abstract description 2
- 239000004615 ingredient Substances 0.000 abstract 3
- 230000009758 senescence Effects 0.000 abstract 2
- 210000003491 skin Anatomy 0.000 description 27
- 239000000523 sample Substances 0.000 description 16
- 238000000034 method Methods 0.000 description 13
- 238000012360 testing method Methods 0.000 description 12
- 230000000694 effects Effects 0.000 description 11
- 239000005018 casein Substances 0.000 description 10
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 10
- 235000021240 caseins Nutrition 0.000 description 10
- 210000004207 dermis Anatomy 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 8
- 230000032683 aging Effects 0.000 description 7
- 235000013336 milk Nutrition 0.000 description 7
- 239000008267 milk Substances 0.000 description 7
- 210000004080 milk Anatomy 0.000 description 7
- 239000006228 supernatant Substances 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 230000007423 decrease Effects 0.000 description 6
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 239000008213 purified water Substances 0.000 description 5
- 238000010998 test method Methods 0.000 description 5
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 4
- -1 Polyoxyethylene lauryl ether Polymers 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 239000003205 fragrance Substances 0.000 description 4
- 239000010410 layer Substances 0.000 description 4
- 239000003755 preservative agent Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 206010015150 Erythema Diseases 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000010908 decantation Methods 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 231100000321 erythema Toxicity 0.000 description 3
- 238000005194 fractionation Methods 0.000 description 3
- 239000004310 lactic acid Substances 0.000 description 3
- 235000014655 lactic acid Nutrition 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 230000002335 preservative effect Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 108090000746 Chymosin Proteins 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 239000004166 Lanolin Substances 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 210000003969 blast cell Anatomy 0.000 description 2
- 230000001055 chewing effect Effects 0.000 description 2
- 229940080701 chymosin Drugs 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- LQZZUXJYWNFBMV-UHFFFAOYSA-N dodecan-1-ol Chemical compound CCCCCCCCCCCCO LQZZUXJYWNFBMV-UHFFFAOYSA-N 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 210000002744 extracellular matrix Anatomy 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 2
- 229940039717 lanolin Drugs 0.000 description 2
- 235000019388 lanolin Nutrition 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 230000004660 morphological change Effects 0.000 description 2
- GNOLWGAJQVLBSM-UHFFFAOYSA-N n,n,5,7-tetramethyl-1,2,3,4-tetrahydronaphthalen-1-amine Chemical compound C1=C(C)C=C2C(N(C)C)CCCC2=C1C GNOLWGAJQVLBSM-UHFFFAOYSA-N 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 230000010627 oxidative phosphorylation Effects 0.000 description 2
- 230000036284 oxygen consumption Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 2
- 230000007306 turnover Effects 0.000 description 2
- 238000000108 ultra-filtration Methods 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 206010063560 Excessive granulation tissue Diseases 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 241000758791 Juglandaceae Species 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241000590428 Panacea Species 0.000 description 1
- 206010033733 Papule Diseases 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- PPWHTZKZQNXVAE-UHFFFAOYSA-N Tetracaine hydrochloride Chemical compound Cl.CCCCNC1=CC=C(C(=O)OCCN(C)C)C=C1 PPWHTZKZQNXVAE-UHFFFAOYSA-N 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000013566 allergen Substances 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000012888 dietary physiology Nutrition 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 210000001840 diploid cell Anatomy 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 229960001596 famotidine Drugs 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 210000001126 granulation tissue Anatomy 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000002853 nucleic acid probe Substances 0.000 description 1
- RMKBWGCMGGWGHF-UHFFFAOYSA-N octadecanoic acid;propane-1,2-diol;propane-1,2,3-triol Chemical compound CC(O)CO.OCC(O)CO.CCCCCCCCCCCCCCCCCC(O)=O RMKBWGCMGGWGHF-UHFFFAOYSA-N 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 230000032696 parturition Effects 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229920000259 polyoxyethylene lauryl ether Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 235000021067 refined food Nutrition 0.000 description 1
- 229940108461 rennet Drugs 0.000 description 1
- 108010058314 rennet Proteins 0.000 description 1
- 230000008521 reorganization Effects 0.000 description 1
- 238000005185 salting out Methods 0.000 description 1
- 238000005464 sample preparation method Methods 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 230000008491 skin homeostasis Effects 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- KKCBUQHMOMHUOY-UHFFFAOYSA-N sodium oxide Chemical compound [O-2].[Na+].[Na+] KKCBUQHMOMHUOY-UHFFFAOYSA-N 0.000 description 1
- 229910001948 sodium oxide Inorganic materials 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 229940032094 squalane Drugs 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
- 235000020234 walnut Nutrition 0.000 description 1
- 235000021119 whey protein Nutrition 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Landscapes
- Cosmetics (AREA)
Abstract
Description
【発明の詳細な説明】
〔産業上の利用分野〕
本発明はコラーゲン合成冗進作用を有する噛乳動物の乳
清及びその分画成分を含有することを特徴とする皮膚化
粧料(医薬部外品たる薬用化粧品を含む.以下同じ)に
関する.
〔従来の技術〕
老齢化社会を迎えつつあるわが国において、老化(エー
ジング)に対する医学的関心が高まる中、皮膚科領域に
おいても皮膚の老化メカニズム等に関する研究が進めら
れ、特に、細胞賦活剤の投与による老化制御に内外の注
目が集まっている.従来、いくつかの動植物及び菌類の
抽出物に組織賦活能が認められ、医薬品や化粧品に用い
られてきた.しかしこれらのものの中で、細胞レベルに
おいて生理活性を有する物質として評価されたものは少
なく、例えば、組織切片に対するこれらの抽出物の添加
による#素の消費量の増加を、ワールプルグ検圧計等を
用いて測定する方法、あるい祉また、ATP等の酸化的
リン酸化を触媒するような酵素を用いた定量法が試みら
れている.しかしながら、これらの手段では、例えば、
組織切片を用いた酸素消費量試験法によれば、水もまた
賦活能を示し、極端なことを言えば炭素や窒素源′をも
った多くのものは適量の濃度にあって酸素の消費量の増
加を示す.少なくとも栄養剤としての評価にはこれらの
測定手段は有効であるが、細胞レベルで皮膚の機能をと
らえ検体の評価を行なうとき、これらの手段により細胞
賦活薫をとらえることは無理な点が多かった.
〔発明が解決しようとする問題点〕
い抵抗力とを有することにより、その生理機能を充分に
果たしている.
皮膚を組織学的に大別すると、表皮、真庶、皮下組織に
分けられるが、特に真皮は皮膚の支持組織として、皮膚
の恒常性維持のために重要な役割を果たしている.真皮
の主な構成細胞は線維芽細胞であり、コラーゲン等の蛋
白質やヒアルロン酸などのグリコサミノグリカンを産生
し、これらの結合組織成分の中で構築構造を形成してい
る.加齢に伴う皮膚の形態的変化としては、まず、皮膚
組織の厚さの減少及び萎縮が知られている(Marks
.R. . Biochemistry and Ph
ysiology of theSkin. Oxfo
rd University Press. 1983
Lまた、皮膚のねじれ伸張性は減少し、弾性回復力が
低下し、更にクルミが増し、やがて老人の皮膚にみられ
る最も特徴的変化であるところの皺(しわ)を形成する
に至る。DETAILED DESCRIPTION OF THE INVENTION [Field of Industrial Application] The present invention relates to a skin cosmetic (non-medicinal) characterized by containing whey of a mammalian animal and its fractionated components, which have a collagen synthesis enhancing effect. (including high-quality medicated cosmetics (the same applies hereinafter)). [Prior art] In Japan, which is facing an aging society, medical interest in aging is increasing, and research into the mechanism of skin aging is progressing in the field of dermatology, with particular emphasis on the administration of cell activators. The control of aging is attracting attention at home and abroad. Extracts from several plants, animals, and fungi have been found to have tissue activating ability and have been used in pharmaceuticals and cosmetics. However, few of these substances have been evaluated as physiologically active substances at the cellular level. Attempts have also been made to measure oxidative phosphorylation using enzymes that catalyze oxidative phosphorylation of ATP, etc. However, with these means, e.g.
According to the oxygen consumption test method using tissue sections, water also shows activating ability, and to put it in an extreme case, many carbon and nitrogen sources have low oxygen consumption at appropriate concentrations. shows an increase in These measurement methods are effective at least for evaluation as nutritional supplements, but when assessing skin functions at the cellular level and evaluating samples, there are many points where it is impossible to use these methods to capture cell activation scent. .. [Problems to be solved by the invention] By having a strong resistance, it satisfactorily fulfills its physiological functions. Histologically, the skin can be roughly divided into the epidermis, dermis, and subcutaneous tissue, and the dermis in particular plays an important role in maintaining skin homeostasis as a support tissue for the skin. The main constituent cells of the dermis are fibroblasts, which produce proteins such as collagen and glycosaminoglycans such as hyaluronic acid, and form structural structures among these connective tissue components. The first known morphological changes in the skin associated with aging include a decrease in skin tissue thickness and atrophy (Marks
.. R. .. Biochemistry and Ph
ysiology of theSkin. Oxford
rd University Press. 1983
In addition, the torsional extensibility of the skin decreases, the elastic recovery power decreases, and the walnuts further increase, eventually leading to the formation of wrinkles, which are the most characteristic changes seen in the skin of the elderly.
一方、真皮の加齢に伴なって生じる最も大きな生化学変
化は、細胞外マトリックスの主成分であるコラーゲンに
認められる.即ち、皮膚コラーゲン量は20歳から80
歳までの間に65%減少し、真皮の厚さは薄くなる(
Shuster.S. * BritishJourn
al of Dermato1ogy.93,639.
1975 ).また、コラーゲンの代謝回転率も加齢に
より低下し生体内に長時間存在するため、コラーゲンS
維中に無秩序な分子間架橋や糖化等が進行し、非可溶性
コラーゲンが増加し( Lagrand.Y.. Pa
thologicalBiology. 17. 99
1. 1969 )、細胞外マトリックスノ硬化の原因
となる.
これらの研究の結果より、真皮1!雑芽細胞のコラーゲ
ン合成を特異的に冗進することができれば、真皮のコラ
ーゲン含有量が増加し真皮の厚さを増し、それに伴って
代謝回転も活性化され、可溶性コラーゲンが増加するこ
とにより細胞外マトリックスの柔軟性、伸展性を改善し
、その結果皺に代表される老化皮膚の形態的変化を抑制
できる可能性がある.
本発明は真皮の線雑芽細胞のコラーゲン合成を〔問題を
解決するための手段〕
本発明者らは、まず細胞レベルで、検体の評価を行なう
ため培養線維芽細胞を用いたコラーゲン合成能試馳法を
確立した.
即ち、本試験法は、培養面全体に単層を形成する直前の
状態( subconfluent )まで培養したヒ
ト線維芽細胞に、検体と同時に放射性同位元素で標識し
たプロリン((’H)一プロリン)を添加して更に培養
を続け細胞内に取り込ませた後、その培養土清と細胞画
分とから、一方で◆ま総蛋白質量として( ’H )一
プロリン量を、もう一方ではコラーゲナーゼ処理して得
られたトリクロロ酢酸(TCA)可溶画分の〔1H〕−
プロリン量を測定し、合成コラーゲン量を定量するもの
である。On the other hand, the most significant biochemical changes that occur with aging in the dermis are observed in collagen, the main component of the extracellular matrix. In other words, the amount of collagen in the skin decreases to 80% from the age of 20.
By age, the thickness of the dermis decreases by 65%, and the thickness of the dermis becomes thinner (
Shuster. S. * British Journal
al of Dermatolology. 93,639.
1975). In addition, the turnover rate of collagen decreases with age and remains in the body for a long time, so collagen S
Disordered intermolecular cross-linking and saccharification progress in the fibers, and insoluble collagen increases (Lagland. Y. Pa.
thological Biology. 17. 99
1. (1969), which causes hardening of the extracellular matrix. From the results of these studies, dermis 1! If it were possible to specifically accelerate collagen synthesis in miscellaneous blast cells, the collagen content in the dermis would increase and the thickness of the dermis would increase, along with activation of turnover and increase in soluble collagen, which would lead to cell growth. It improves the flexibility and extensibility of the outer matrix, and as a result, it may be possible to suppress morphological changes in aging skin, such as wrinkles. The present invention aims to improve the collagen synthesis of dermal miscellaneous blast cells [Means for solving the problem] The present inventors first conducted a collagen synthesis ability test using cultured fibroblasts to evaluate the specimen at the cellular level. Established the method. In other words, in this test method, human fibroblasts that have been cultured to a state just before forming a monolayer on the entire culture surface (subconfluent) are injected with radioisotope-labeled proline (('H)-proline) at the same time as the specimen. After adding and further culturing to incorporate into the cells, the culture medium and cell fraction were treated with ◆ and ('H) monoproline as the total protein amount on the one hand, and collagenase treatment on the other hand. [1H]- of the trichloroacetic acid (TCA) soluble fraction obtained by
The amount of proline is measured and the amount of synthetic collagen is quantified.
本発明者らは、動植物及び菌類より任意に選んだ種々の
物質について、そのコラーゲン合成冗進作用を上述の試
験法にてスクリーニングした結果、呻乳動物の乳清及び
その分画成分に高いコラーゲン合成冗進活性を認めるに
至った。The present inventors screened various substances arbitrarily selected from animals, plants, and fungi for their collagen synthesis stimulatory effects using the above-mentioned test method. Synthetic redundant activity was recognized.
乳清は乳汁からカゼインと脂肪を除去した後に残る画分
て、牛乳からはチーズやカゼイン製造時の副産物として
得られる.また古代ギリシャではヒボクラテスにより自
然薬の一つとして、体の洗浄、利尿、解毒、機能増進、
体力向復、便秘の治療などに万能薬的食品として乳清が
利用されていた.現在でも乳清は飲料等に利用され、特
に栄養生理学、予防医学的にその意義が認められている
.また、乳清まり得られる蛋白質(ホエーたんぱく濃縮
物.wpc)は、そのゲル形成性、保水性などの優れた
機能特性からハム、ソーセージ等加工食品向けに需要が
ある.
しかしながら、これまで噛乳動物の乳清及びその分画成
分のコラーゲン合成冗進作用、またはその皮膚化粧料へ
の配合における有用性に関する研究は全くなされておら
ず、本発明者らにより初めて明らかにされたものである
.
即ち、哺乳動物の乳清のコラーゲン合成冗進作用は、分
娩後5日以内の初乳清に特に高く認めら動物の乳清及び
その分画成分を配合した皮膚化粧料を調製し皮膚に塗布
したところ、皮膚機能を冗進し、肌の皺を防止し、きめ
細やかな、かつしっとりした皮膚にすることを発見し、
また、その高い安全性を確認したため、本発明を完成す
るに至った.なお、本発明のコラーゲン合成充進作用を
有する噛乳動物の乳清及びその分画成分を配合した皮膚
化粧料は、真皮の線維芽細胞のコラーゲン合成を特異的
に冗進することにより、その効果をあらわすものと考え
られた.
また、本発明の皮膚化粧料は組織損傷時、創床部に遊走
したam芽細胞により形成される肉芽組織に作用し、そ
のコラーゲン合成を先進し真皮の再構成を促すことによ
り創傷治癒効果を有することも期待される.
即ち、本発明は、コラーゲン合成冗進作用を有する哺乳
動物の乳清及びその分画成分を含有することを特徴とす
る新規な皮膚化粧料を提供するものである.
以下、本発明につき詳述する.
本発明に至る過程で用いた先述のコラーゲン合成能試験
法は本発明のコラーゲン合成冗進作用を制限するもので
はなく、細胞レベルでコラーゲン合成能を検出し得る他
の試験法、例えば、放射性同位元素で標識したヒドロキ
シブロリンを用いる方法、コラーゲンの抗体を用いる免
疫学的方法、コラーゲンのmRNAを核酸プロープとハ
イプリダイズさせ検出する方法等をin vitro,
in vivo, in aituで利用することが
できる.本発明に使用する乳清は、まず、ヒト、ウシ、
ヤギ、ヒツジ、ブタ等の哺乳動物から採取された新鮮な
乳汁、或いはその乳汁を予め乾燥粉末化した後水に溶解
したものが用いられ、通常、遠心分離によって最上層の
脂肪分を除いて脱脂後、種々の方法でカゼイン画分を除
去し得られる.カゼイン画分の除去法は通常、大きく二
つの方法に分けられる.一つは乳酸、塩酸、硫酸等の酸
の添加に.J:’)pH4.4〜4.6程度の酸性でカ
ゼインを等電点沈殿させ、もう一つはキモシン等の酵素
の作用によりカゼインを凝固させ、いずれも不溶化した
カゼイン画分を濾過、遠心分離或いはデヵンテーション
等により除去する方法で行なわれ、得られるカゼイン画
分は、前者を酸カゼイン、後者をレンネットカゼインと
呼ぶ.
なお、噛乳動物の分娩後5日以内に採取される初乳から
得られる初乳清中のコラーゲン合成冗進作用が、特に高
いことが明らかとなり、従来、初乳中にはグロプリン含
量が多いことが知られていることからも、生理学上、重
要な意味をもつものと考えられる.
更に本発明者らは、乳清中のコラーゲン合成冗進作用の
分画法につき研究した結果、乳清の酸・アルコール処理
により可溶画分に効率的に移行することを発見した.ま
た、得られた酸・アルコール可溶画分は清澄で安定な溶
液であり、皮膚化粧料想方上、その原料として有利な性
状であり、更に蛋白質等、アレルゲンとなりうる高分子
物質濃度が著しく低減されるため、安全性も向上する。Whey is the fraction that remains after casein and fat are removed from milk, and is obtained from milk as a by-product during the production of cheese and casein. In ancient Greece, Hibocrates used it as a natural medicine to cleanse the body, diuretic, detoxify, and improve function.
Whey was used as a panacea for improving physical strength and treating constipation. Even today, whey is used in beverages and other products, and its significance is particularly recognized in terms of nutritional physiology and preventive medicine. In addition, the protein obtained from whey (whey protein concentrate.wpc) is in demand for processed foods such as ham and sausages due to its excellent functional properties such as gel-forming and water-retaining properties. However, until now, no research has been conducted on the collagen synthesis enhancing effect of whey from chewing mammals and its fractionated components, or on its usefulness in blending into skin cosmetics. This is what was done. In other words, the collagen synthesis enhancing effect of mammalian whey is particularly high in colostrum produced within 5 days after delivery.A skin cosmetic containing animal whey and its fractionated components is prepared and applied to the skin. They discovered that it enhances skin function, prevents wrinkles, and makes skin smooth and moisturized.
Furthermore, we have confirmed its high safety, which led us to complete the present invention. The skin cosmetics of the present invention containing mammalian whey and its fractionated components that have collagen synthesis-enhancing effects specifically enhance the collagen synthesis of fibroblasts in the dermis. This was thought to indicate an effect. In addition, the skin cosmetic of the present invention acts on the granulation tissue formed by amblasts that have migrated to the wound bed at the time of tissue damage, advances collagen synthesis, and promotes dermal reorganization, thereby exerting a wound healing effect. It is also expected that That is, the present invention provides a novel skin cosmetic product characterized by containing mammalian whey and its fractionated components, which have a collagen synthesis enhancing effect. The present invention will be explained in detail below. The above-mentioned collagen synthesis ability test method used in the process leading to the present invention does not limit the collagen synthesis redundancy effect of the present invention, and other test methods that can detect collagen synthesis ability at the cellular level, such as radioisotope In vitro, methods using hydroxybroline labeled with elements, immunological methods using collagen antibodies, and detection methods by hybridizing collagen mRNA with nucleic acid probes, etc.
It can be used in vivo and in situ. The whey used in the present invention is first of all human, bovine,
Fresh milk collected from mammals such as goats, sheep, and pigs, or milk that has been previously dried and powdered and then dissolved in water, is used, and is usually defatted by removing the fat in the top layer by centrifugation. After that, the casein fraction can be removed using various methods. Methods for removing casein fractions are generally divided into two main methods. One is for adding acids such as lactic acid, hydrochloric acid, and sulfuric acid. J:') Casein is isoelectrically precipitated with acidic pH of about 4.4 to 4.6, and casein is coagulated by the action of enzymes such as chymosin, and the insolubilized casein fraction is filtered and centrifuged. It is removed by separation or decantation, and the resulting casein fractions are called acid casein and rennet casein. In addition, it has been revealed that colostrum obtained from colostrum collected within 5 days after parturition of chewing mammals has a particularly high collagen synthesis enhancing effect, and conventionally, colostrum contains a high globulin content. Since this is known, it is considered to have important physiological significance. Furthermore, as a result of research into a fractionation method for collagen synthesis redundancy in whey, the present inventors discovered that whey is efficiently transferred to a soluble fraction by acid/alcohol treatment. In addition, the obtained acid/alcohol soluble fraction is a clear and stable solution, which is advantageous as a raw material for skin cosmetics, and the concentration of polymeric substances such as proteins that can be allergens is significantly reduced. This also improves safety.
以下に酸・アルコール想理条件につき詳細に説明するが
、本質的に呻乳動物の乳清に存在するコラーゲン合成冗
進作用成分は、種々の方法、例えば、脱乳糖、脱塩、溶
剤分画、塩析、限外濾過、ゲル濾過、イオン交換法等に
よっても分画、精製或いは濃縮することができる.
本発明の乳清の酸・アルコール可溶画分の調製に当って
は、まず、上述にある如く調製された乳清、或いはその
乳清を予め乾燥粉末化された後水に溶解したものを用い
、酸及びアルコールを別々に加えるか、または酸・アル
コール混液として加え、最終pH1〜5、アルコール濃
度10〜50%(V/V)好ましくはpH2.0〜4.
5、7 4 −z−ル濃度30〜40%(V/V)に調
整する.pH1未満、またはアルコール濃度50%(V
/v)以上では、コラーゲン合成冗進作用の作用成分が
失活或いは不溶化を起こす。また、pH5以上またはア
ルコール濃度10%(v/V)以下、或い辻酸もしくは
アルコールのどちらか一方だけの処理では、不等の方法
により濃縮してもよく、また、凍結乾燥、噴霧乾燥或い
は平板乾燥等の方法により乾燥粉末化することも可催で
ある.
本発明の皮膚化粧料は、化粧水、クリーム、乳液、パッ
クなど外用可能な任意の剤形であってよく、コラーゲン
合成冗進作用を有する呻乳動物の乳清及びその分画成分
の配合量も、症状の程度、剤形などによって適宜変更で
きる.また、その基エタノール、インプロパノール、n
−ブタノール等任意のものが用いられるが、好ましくは
エタノールが用いられる.また、使用する酸も塩酸、酢
酸、乳酸、硫酸、クエン酸、リン酸等特に限定するもの
ではない.酸・アルコール処理の結果、生じる不溶物は
濾過、遠心分離或いはデカンテーション等により除去し
、.コラーゲン合成冗進作用成分を豊富に含有する可溶
画分が得られる.更に、酸・アルコール可溶画分は必要
に応じてpHを中性に調整し、減圧濃縮、限外濾過或い
は凍結濃縮とができる.
〔作用〕
かくして得られる本発明の皮膚化粧料の有効性及び安全
性について試験した結果は、次のとおりである.
隻鷺適1 培養w&維芽細胞のコラーゲン合成能試験
継代維持してきたW4−38細胞(ヒト胎児肺正常2倍
体細胞,PDL40)を、試験前日に新しいMEM培地
(10%牛胎児血清含有)に培地交換し24時間培養(
precultura )後、培養上清に試料を添加
、〔aH〕−ブロリンを終濃度2μCiとなる様添加し
、6時間、5%Co,+95%Air.37℃で培養し
た.なお、試料無添加区を対照とした.その後培養上清
を取り除き、細胞画分にフラ〜ゲナーゼタイブN (
Worthington社製) 5 units/ml
を37℃,18時間作用させ、トウントしコラーゲン量
とした.
なお、非コラーゲン蛋白質量は、フラーゲナーゼ無処理
の総〔1H〕−プロリン量からコラーゲン量を差し引い
た値として表わした.
その結果を第1表に示す.
試料の調製法と培地への試料添加量を下記する。The acid/alcohol ideal conditions will be explained in detail below, but the collagen synthesis-enhancing components essentially present in the whey of mammalian animals can be processed by various methods, such as delactose, desalt, and solvent fractionation. It can also be fractionated, purified, or concentrated by salting out, ultrafiltration, gel filtration, ion exchange methods, etc. In preparing the acid/alcohol soluble fraction of whey of the present invention, first, the whey prepared as described above, or the whey that has been previously dried and powdered and then dissolved in water, is prepared. The acid and alcohol are added separately or as a mixture of acid and alcohol, with a final pH of 1 to 5 and an alcohol concentration of 10 to 50% (V/V), preferably a pH of 2.0 to 4.
5,7 Adjust the 4-z-le concentration to 30-40% (V/V). pH less than 1 or alcohol concentration 50% (V
/v) or higher, the active ingredient for collagen synthesis redundancy becomes inactivated or insolubilized. In addition, in cases where the pH is 5 or more, the alcohol concentration is 10% (v/v) or less, or only one of citric acid or alcohol is used, concentration may be performed by an unequal method, and freeze-drying, spray-drying, or It is also possible to dry and powder it by methods such as plate drying. The skin cosmetic of the present invention may be in any form that can be used externally, such as lotion, cream, milky lotion, or pack, and contains the amount of whey from a mammalian animal that has a collagen synthesis enhancing effect and its fractionated components. The dosage can also be changed as appropriate depending on the severity of symptoms, dosage form, etc. Also, its groups ethanol, inpropanol, n
-Any substance such as butanol can be used, but ethanol is preferably used. Furthermore, the acids used are not particularly limited, such as hydrochloric acid, acetic acid, lactic acid, sulfuric acid, citric acid, and phosphoric acid. Insoluble matter generated as a result of the acid/alcohol treatment is removed by filtration, centrifugation, decantation, etc. A soluble fraction rich in components that enhance collagen synthesis can be obtained. Furthermore, the pH of the acid/alcohol soluble fraction can be adjusted to neutrality if necessary, and the fraction can be concentrated under reduced pressure, ultrafiltrated, or frozen. [Effect] The results of testing the effectiveness and safety of the skin cosmetics of the present invention thus obtained are as follows. 1. Collagen synthesis ability test of cultured w&fibroblasts W4-38 cells (human fetal lung normal diploid cells, PDL40), which have been maintained for generations, were added to fresh MEM medium (containing 10% fetal bovine serum) on the day before the test. ) and cultured for 24 hours (
precultura), the sample was added to the culture supernatant, [aH]-brolin was added to a final concentration of 2 μCi, and the mixture was incubated for 6 hours in 5% Co, +95% Air. Cultured at 37°C. In addition, the sample-free plot was used as a control. After that, the culture supernatant was removed, and the cell fraction was divided into furagenase type N (
Worthington) 5 units/ml
was allowed to act at 37°C for 18 hours, and the amount of collagen was determined by torn. The non-collagen protein amount was expressed as the value obtained by subtracting the collagen amount from the total [1H]-proline amount without fullagenase treatment. The results are shown in Table 1. The sample preparation method and the amount of sample added to the medium are described below.
試料A :1ラーゲン合成冗進作用を有するウシ乳清
ウシの脱脂粉乳(常乳)570gを脱イオン水4.51
と混合し、IM酢@700mj!を加えpH4.4に調
整し、2時間攪拌、5℃で一夜放置した後、遠心分離(
700gx30min ) L,、その上清をセライ
ト濾過し清澄な乳清を得た。Sample A: 1 Bovine whey with lagen synthesis redundancy effect 570 g of bovine skim milk powder (conventional milk) was mixed with 4.5 g of deionized water.
Mix with IM vinegar @700mj! was added to adjust the pH to 4.4, stirred for 2 hours, left overnight at 5°C, and then centrifuged (
700g x 30min) L, and the supernatant was filtered through Celite to obtain clear whey.
試料B コラーゲン合成充進作用を有するウシ初乳清
ウシの分娩後2〜3日経過時に採取された初乳10Nを
遠心分ll( 15000gX30min )t,、最
上層の脂肪分を除去した後、30℃に加温、適量のキモ
シンを加え2時間攪拌後、遠心分XI ( 720gx
30min)シ、その上清をメンプランフィルターにて
濾過し清澄な初乳清を得た。Sample B: Bovine colostrum with collagen synthesis enhancing effect 10N of colostrum collected from cows 2 to 3 days after calving was centrifuged (15000g x 30min), after removing the fat in the uppermost layer, ℃, add an appropriate amount of chymosin, stir for 2 hours, and centrifuge XI (720 g
30 min), and the supernatant was filtered using a Membrane filter to obtain clear colostrum.
試料C コラーゲン合成充進作用を有するウシ乳清の分
画或分
試料Aで得られたウシ乳清5lを減圧下、10倍濃縮し
、4℃まで冷却した時析出する乳糖を除いた後、水を加
え5lまで戻した.これにエタノール2.82と濃塩酸
60m2との混合液を加え、ホモミキサーで2時間混和
した.その後遠心分離( 700gx30min )L
,、その上清6lにIN+,酸化ナトリウム0.21を
加えpH7.0とし、減圧下、22まで濃縮し濾過して
清澄な乳清分画成分を得た.
試料D コラーゲン合成光進作用を有するウシ初乳清の
分画成分
試料Bで得られたウシ初乳清5Qにメタノール32を混
和し、酢酸でpH3.0とし、更にホモミキサーで2時
間混合した.その後デカンテーションにて上清を分取し
、分画分子量1万の限外濾過膜で2倍濃縮し、セライト
濾過により清澄な初乳清分画成分を得た.
試料E コラーゲン合成冗進作用を有するヤギ乳清の分
画成分
ヤギより採取された乳汁102を遠心分II( 150
00gx30min ) t,、最上層の脂肪分を除去
した後、乳酸を加えpH4 .5に調整し、2時間攪拌
、5℃で一夜放置した後、遠心分離( 700gx30
min ) L,、その上清をセライト濾過し清澄な乳
清を得た.この乳清61にn−プタノール3.42と酢
酸70mlの混液を加え、その後遠心分離( 700g
X30sin)L、その上清42にIN水酸化ナトリウ
ムを加えpH6.5とし、減圧下31まで濃縮し濾過し
て清澄な乳清分画成分を得た。Sample C: Fractionation of bovine whey that has the effect of promoting collagen synthesis. 5 liters of the bovine whey obtained in Sample A was concentrated 10 times under reduced pressure, and after removing the lactose that precipitated when cooled to 4°C, Add water to bring the volume back up to 5 liters. A mixture of 2.82 ml of ethanol and 60 m2 of concentrated hydrochloric acid was added to this, and mixed for 2 hours using a homomixer. Then centrifugation (700g x 30min)
,, IN+, sodium oxide 0.21 was added to 6 liters of the supernatant to adjust the pH to 7.0, and the mixture was concentrated under reduced pressure to 22 and filtered to obtain a clear whey fraction. Sample D Fractionated component of bovine colostrum having collagen synthesis photostimulation activity Bovine colostrum 5Q obtained in sample B was mixed with methanol 32, adjusted to pH 3.0 with acetic acid, and further mixed for 2 hours in a homomixer. Thereafter, the supernatant was collected by decantation, concentrated twice using an ultrafiltration membrane with a molecular weight cutoff of 10,000, and filtered through Celite to obtain a clear colostrum fraction. Sample E Fractional component of goat whey that has a collagen synthesis enhancing effect Milk 102 collected from a goat was centrifuged with
00g x 30min) t, After removing the fat from the top layer, add lactic acid and adjust to pH 4. 5, stirred for 2 hours, left overnight at 5℃, and centrifuged (700g x 30℃).
min) L, the supernatant was filtered through Celite to obtain clear whey. A mixture of 3.42 ml of n-butanol and 70 ml of acetic acid was added to this whey 61, and then centrifuged (700 g
X30sin)L, its supernatant 42 was adjusted to pH 6.5 by adding IN sodium hydroxide, concentrated under reduced pressure to 31 and filtered to obtain a clear whey fraction.
試料F コラーゲン合成冗進作用を有するヒッジ乳清
ヒツジより採取された乳汁102を遠心分離(1500
0gX30min ) I,、最上層の脂肪分を除去し
た後IM塩酸1.12を加えpH4 .5に調整し、2
時間攪拌、5℃で一夜放置した後、遠心分離(700g
X30min ) シ、その上清をセライト濾過し清澄
な乳清を得た.
添加量(V/V培地X)
試料A: 5%
試料B: 5%
試料C: 2%
試料D= 2%
試料E: 2%
試料F: 5%
簸1遺
第1表より明らかな様に嘘乳動物の乳清及びその分画或
分は、線維芽細胞のコラーゲン合成を有意に、また特異
的に冗進することが明らかとなった.
区致班1 バネルテスト
小皺の悩みを有する31〜52歳(平均年齢40.1歳
)の女性50名を対象にして、下記の本発明皮膚化粧料
及び対照皮膚化粧料を、1日2回(朝、夕)連続3ケ月
塗布、使用せしめた結果の官能評価を第2表に示す.
〈本発明皮膚化粧料及び対照皮膚化粧料〉試験例1の試
料A
(対照皮膚化粧料は精製水) 202グリセ
リン 5xエタノール
5zメチルパラベン
0.1x精製水
69.9X皐:対照との間に信頼度99%で
有意差あり(n=4)第2表より明らかな様に、本発明
の皮膚化粧料は高い有効性を示すことが明らかとなった
.莱1貞
較捩班1 パッチテスト
年齢21〜64歳までの男性17名、女性13名、計3
0名からなる被検者の上腕屈側部に、クローズドパッチ
テストを実施した.試料として実施例1のウシ乳清を用
いた.
判定の基準 −:全く無反応,±:軽微な紅斑,十;明
らかな紅斑,++;紅斑及び腫張、丘疹その結果、全被
検者において、一(全←無反応)であり、刺激反応及び
アレルギー反応を惹起する可能性は非常に少なく、安全
性の高いことが明らかとなった.
〔実施例〕
以下に本発明の実施例を示すが、これらによって本発明
を制限するものではない.
裏集負ユ
〈化粧水〉
グリセリン 5xプロビレ
ングリコール 4z才レイルアルコ
ール 0.1xボリオキシエチレン
ソルビタンモノラウリ1.5Xン酸エステル
ボリ才キシエチレンラウリルエーテル 0.5xエタ
ノール 10x試験例1
の試料A 20%香料,染料,
防腐剤,紫外線吸収剤 適量精製水
58.92犬蓋輿1
〈クリーム〉
ステアリン酸
ステアリルアルコール
還元ラノリン
スクワラン
才クチルドデカノール
ポリ才キシエチレンセチルエーテル
親油型モノステアリン酸グリセリン
プロピレングリコール
試験例1の試料B
香料,防腐剤,酸化防止剤
精製水
夫隻班1
く乳液〉
ステアリン酸
セタノール
ワセリン
ラノリンアルコール
流動パラフィン
ボリ才キシエチレンモノ才レイ
グリセリン
0.2x
1.5x
3x
2X
10X
ン酸エステル2x
3x
プロピレングリコール 5xトリエ
タノールアミン 1x試験例1の
試料C 15%香料,防腐剤,
#化防止剤 適量精製水
57.3X夾凰斑1
くパック〉
ポリビニルアルコール 15X力ルボ
キシメチルセルロースナトリウム 5xブロピレング
リコール 3xエタノール
10%試験例1の試料E
5X香料,防腐剤,酸化剤
適量精製水
62%〔発明の効果〕
以上詳述した如く、本発明のコラーゲン合成充進作用を
有する咄乳動物の乳清及びその分画成分を含有すること
を特徴とする皮膚化粧料は、皮膚機能を冗進し、肌の皺
を防止し、きめ細やかな、かつしっとりした皮膚にする
老化制御機能を有しまた安全性も高いため、
臨床上の応用が十分に
期待される.
したがって、
本発明の産業上の意義
は非常に大きい.Sample F: Milk 102 collected from a hedge whey sheep with collagen synthesis hyperactivity was centrifuged (1500
0g x 30min) I, After removing the fat from the top layer, add IM hydrochloric acid 1.12 to pH 4. Adjust to 5, then 2
After stirring for an hour and leaving it at 5℃ overnight, centrifugation (700g
x30min) The supernatant was filtered through Celite to obtain clear whey. Addition amount (V/V medium It has been revealed that whey from lying mammals and its fractions significantly and specifically enhance collagen synthesis in fibroblasts. Ward Team 1 Bunnell Test The following skin cosmetics of the present invention and control skin cosmetics were administered twice a day to 50 women aged 31 to 52 (average age: 40.1 years) suffering from fine wrinkles. Table 2 shows the sensory evaluation of the results of applying and using the product (morning and evening) for three consecutive months. <Skin cosmetics of the present invention and control skin cosmetics> Sample A of Test Example 1 (control skin cosmetics are purified water) 202 glycerin 5x ethanol
5z methylparaben
0.1x purified water
69.9X: There was a significant difference from the control with a confidence level of 99% (n = 4) As is clear from Table 2, it became clear that the skin cosmetics of the present invention showed high effectiveness. .. Patch test 17 men and 13 women between the ages of 21 and 64, total 3
A closed patch test was performed on the flexor side of the upper arm of 0 subjects. The bovine whey from Example 1 was used as a sample. Judgment criteria -: No reaction at all, ±: Slight erythema, 10: Obvious erythema, ++: Erythema and swelling, papules As a result, in all subjects, 1 (all ← no reaction), irritation reaction It has been found that the possibility of causing an allergic reaction is extremely low, and that it is highly safe. [Examples] Examples of the present invention are shown below, but the present invention is not limited by these. Back collection lotion Glycerin 5x Probylene glycol 4x Layl alcohol 0.1x Polyoxyethylene sorbitan monolauryl 1.5x Polyoxyethylene lauryl ether 0.5x Ethanol 10x Test example 1
Sample A 20% fragrance, dye,
Preservatives, UV absorbers Appropriate amount of purified water
58.92 Dog Cover 1 <Cream> Stearic acid stearyl alcohol reduced lanolin squalane cutyl dodecanol polyoxyethylene cetyl ether lipophilic monostearic acid glycerin propylene glycol Sample B of Test Example 1 Fragrance, preservative, antioxidant Purified Sailor Boat Group 1 Milky lotion> Stearic acid cetanol Vaseline Lanolin Alcohol Liquid paraffin Polyethylene glycerol 0.2x 1.5x 3x 2X 10X Phosphate ester 2x 3x Propylene glycol 5x Triethanolamine 1x Sample of Test Example 1 C 15% fragrance, preservative,
# Antioxidant Appropriate amount of purified water
57.3X scarlet 1 pack> Polyvinyl alcohol 15X Sodium carboxymethylcellulose 5x Bropylene glycol 3x Ethanol
Sample E of 10% Test Example 1
5X fragrance, preservative, oxidizing agent
Appropriate amount of purified water
62% [Effect of the invention] As detailed above, the skin cosmetic product of the present invention, which is characterized by containing whey of a mammalian mammal and its fractionated components, which has an effect of promoting collagen synthesis, improves skin function. It has aging control functions that prevent wrinkles and make the skin smooth and moisturized, and it is also highly safe, so it has high expectations for clinical application. Therefore, the industrial significance of the present invention is extremely large.
Claims (5)
及びその分画成分を含有することを特徴とする皮膚化粧
料(1) Skin cosmetics characterized by containing mammalian whey and fractionated components thereof that have a collagen synthesis enhancing effect
る特許請求の範囲第1項の皮膚化粧料(2) The skin cosmetic according to claim 1, wherein the mammal is a human, cow, goat, sheep, or pig.
範囲第1項の皮膚化粧料(3) The skin cosmetic according to claim 1, wherein the whey is colostrum produced within 5 days after delivery.
求の範囲第1項の皮膚化粧料(4) The skin cosmetic according to claim 1, wherein the fractionated component is an acid/alcohol soluble fraction.
ル濃度10〜50%(V/V)で処理し、不溶物を除去
して得られる特許請求の範囲第4項の皮膚化粧料(5) The skin cosmetic according to claim 4, which is obtained by treating the acid/alcohol soluble fraction at a pH of 1 to 5 and an alcohol concentration of 10 to 50% (V/V) to remove insoluble matter.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP1156385A JP2533376B2 (en) | 1989-06-19 | 1989-06-19 | Skin cosmetics |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP1156385A JP2533376B2 (en) | 1989-06-19 | 1989-06-19 | Skin cosmetics |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH0320206A true JPH0320206A (en) | 1991-01-29 |
JP2533376B2 JP2533376B2 (en) | 1996-09-11 |
Family
ID=15626596
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP1156385A Expired - Lifetime JP2533376B2 (en) | 1989-06-19 | 1989-06-19 | Skin cosmetics |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP2533376B2 (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH06345636A (en) * | 1993-06-08 | 1994-12-20 | Nonogawa Shoji Kk | Cosmetic |
JPH1095713A (en) * | 1996-09-20 | 1998-04-14 | Kao Corp | Evaluation of improvement effect for slack of skin |
WO1998040045A1 (en) * | 1997-03-11 | 1998-09-17 | Pola Chemical Industries Inc. | Method for evaluating skin conditioning agents and process for producing external skin preparations |
JP2001072567A (en) * | 1999-09-07 | 2001-03-21 | Sunstar Inc | Skin cosmetic |
WO2004098632A1 (en) * | 2003-05-07 | 2004-11-18 | Snow Brand Milk Products Co., Ltd. | Skin collagen production promoter |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5754108A (en) * | 1980-08-19 | 1982-03-31 | Stauffer Chemical Co | HOEETANPAKUSHITSUGANJUKESHOHINSHOHO |
JPS63269947A (en) * | 1987-04-29 | 1988-11-08 | San Ei Chem Ind Ltd | Fat-or oil-containing product |
JPH01254610A (en) * | 1988-04-01 | 1989-10-11 | Sanko Seibutsu Kagaku Kenkyusho:Kk | Skin cosmetic and production thereof |
-
1989
- 1989-06-19 JP JP1156385A patent/JP2533376B2/en not_active Expired - Lifetime
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5754108A (en) * | 1980-08-19 | 1982-03-31 | Stauffer Chemical Co | HOEETANPAKUSHITSUGANJUKESHOHINSHOHO |
JPS63269947A (en) * | 1987-04-29 | 1988-11-08 | San Ei Chem Ind Ltd | Fat-or oil-containing product |
JPH01254610A (en) * | 1988-04-01 | 1989-10-11 | Sanko Seibutsu Kagaku Kenkyusho:Kk | Skin cosmetic and production thereof |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH06345636A (en) * | 1993-06-08 | 1994-12-20 | Nonogawa Shoji Kk | Cosmetic |
JPH1095713A (en) * | 1996-09-20 | 1998-04-14 | Kao Corp | Evaluation of improvement effect for slack of skin |
WO1998040045A1 (en) * | 1997-03-11 | 1998-09-17 | Pola Chemical Industries Inc. | Method for evaluating skin conditioning agents and process for producing external skin preparations |
JP2001072567A (en) * | 1999-09-07 | 2001-03-21 | Sunstar Inc | Skin cosmetic |
WO2004098632A1 (en) * | 2003-05-07 | 2004-11-18 | Snow Brand Milk Products Co., Ltd. | Skin collagen production promoter |
Also Published As
Publication number | Publication date |
---|---|
JP2533376B2 (en) | 1996-09-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6541447B1 (en) | Wound healing composition and method for use thereof | |
JPH08231370A (en) | Skin cosmetic | |
EP1265570B1 (en) | Soluble keratin peptide | |
JPH09512563A (en) | Extract of shark cartilage having anti-angiogenic activity and effect on tumor regression, and method for producing the same | |
US8722108B2 (en) | Cosmetic and/or pharmaceutical composition comprising an extract of carob as active agent for activating aquaporin expression | |
EP0711171B1 (en) | A pharmaceutical or cosmetic composition comprising a colostrum fraction and its medical use | |
PL187989B1 (en) | Shark cartilage extracts, method of obtaining such extracts and compositions containing them | |
JPH05230100A (en) | Protein fraction, its isolation, effective substance concentrate containing said fraction and preparation for skin care and/or medical treatment of inflammatory skin | |
JP4441123B2 (en) | Use of rosmarinus plant extracts in compositions for treating signs of aging skin | |
JP4291967B2 (en) | Skin collagen production promoter | |
CN110538312A (en) | skin wound repair ointment and preparation method thereof | |
US6506732B1 (en) | Enzymatic hydrolysate of milk proteins | |
KR100828107B1 (en) | A cosmetic composition containing an extract of Ailanthus altissima | |
JP4698935B2 (en) | Skin collagen production promoter | |
JPH0320206A (en) | Skin cosmetic | |
JPH069422A (en) | Promoter for biosynthesis of hyaluronic acid | |
AU2014253131A1 (en) | Synergistic combination of alanine-glutamine, hyaluronic acid and an oat extract and the use thereof in a composition intended for healing wounds and repairing skin lesions | |
JP3213189B2 (en) | Hyaluronic acid production promoter | |
JP3073862B2 (en) | Hyaluronic acid production promoter | |
US4908206A (en) | Extracts of embryonic organs, process for their preparation and pharmaceutical preparation containing them | |
CN110876698B (en) | Active composition for regulating microenvironment of skin cells as well as preparation method and application thereof | |
JPH0665041A (en) | Skin external preparation | |
US20030130195A1 (en) | Enzymatic hydrolysate of milk proteins | |
JPH0710740A (en) | Melamine production-inhibiting agent | |
JPH06128140A (en) | External agent for skin |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20080627 Year of fee payment: 12 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090627 Year of fee payment: 13 |
|
EXPY | Cancellation because of completion of term | ||
S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
R370 | Written measure of declining of transfer procedure |
Free format text: JAPANESE INTERMEDIATE CODE: R370 |